人才建設(shè)

您所在的位置: 首頁(yè) - 人才建設(shè) - 師資隊(duì)伍 - 準(zhǔn)聘長(zhǎng)聘教師 - 教授 - 血液病醫(yī)院

血液病醫(yī)院

  • 姓 名:

    肖志堅(jiān)

  • 單 位:

    中國(guó)醫(yī)學(xué)科學(xué)院血液病醫(yī)院(中國(guó)醫(yī)學(xué)科學(xué)院血液學(xué)研究所)

  • 教職崗位:

    教授

  • 聘任時(shí)間:

    2022-01-01

  • 一級(jí)學(xué)科:

    臨床醫(yī)學(xué)

  • 二級(jí)學(xué)科:

    內(nèi)科學(xué)(血液病)

  • 聯(lián)系方式:

    zjxiao@ihcams.ac.cn

  • 導(dǎo)師風(fēng)采鏈接:
    https://yzbss.pumc.edu.cn/basicinfo/tutorinfo/tutordetail/J2009140224

個(gè)人簡(jiǎn)介

肖志堅(jiān),主任醫(yī)師,教授,博士生導(dǎo)師,副所院長(zhǎng)、MDS診療中心主任,病理中心主任。主要研究髓系腫瘤發(fā)病分子機(jī)制和臨床診治新策略。主持國(guó)家級(jí)、省部級(jí)、院校級(jí)課題共計(jì)27項(xiàng)。牽頭制定了疾病診治指南/共識(shí)共8部,制定了國(guó)家衛(wèi)健委頒布的骨髓增生異常綜合征(MDS)和骨髓增殖性腫瘤(MPN)的診療路徑。在國(guó)際頂尖期刊N Engl J Med、Cancer Discov、Leukemia、Blood等雜志發(fā)表多篇論文,相關(guān)研究成果被國(guó)際指南引用。現(xiàn)為我國(guó)MDS和MPN研究領(lǐng)域的領(lǐng)軍人物。


主要研究?jī)?nèi)容

髓系腫瘤發(fā)病分子機(jī)制和臨床診治新策略。


代表性成果

久久综合九色欧美综合狠狠_伊人热热久久原色播放WWW_成A人片亚洲日本久久_久久不见久久见免费影院www日本_97久久精品人人做人人爽,又色又爽又黄的视频在线观看,狼群影院视频在线观看高清版,亚洲AV无码精品网站性色,国产乱码久久久久久红粉影视,精品国产乱码久久久久久一区二区,国产精品免费视频网站,国产A级毛片久久久久久精品,一级特黄高清aaaa大片,亚洲中文字幕欧美一区,久久精品国产99久久狂热,黑人巨大精品欧美_黑人巨大精品欧美黑寡妇_黑人巨大精品欧美一区二区_黑人巨大精品欧美一区二区免费_黑人巨大跨种族video_黑人巨大无码中文字幕无码_黑人巨茎大战俄罗斯美女_黑人巨茎大战俄罗斯美女,中文字幕av不卡|亚洲欧美国产另类|天天干在线播放|日韩黄视频|欧美七区|可以免费看毛片的网站|黄色片在线|国产精品96久久久久久

1. Liu YC#, Kwon J#, Fabiani E#, Xiao Z#, Liu YV, Follo MY, Liu J, Huang H, Gao C, Liu J, Falconi G, Valentini L, Gurnari C, Finelli C, Cocco L, Liu JH, Jones AI, Yang J, Yang H, Thoms JAI, Unnikrishnan A, Pimanda JE, Pan R, Bassal MA, Voso MT, Tenen DG*, Chai L*. Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy. N Engl J Med. 2022,386(21):1998-2010. (IF=176.079)

2. Liu D#, Xu Z#, Zhang P, Qin T, Sun X, Qu S, Pan L, Ma J, Cai W, Liu J, Wang H, Sun Q, Shi Z, Huang H, Huang G, Gale RP, Li B*, Rampal RK*, Xiao Z*. Conventional interferon-α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center. Haematologica. 2022,107(4):991-995. (IF=11.0479)

3. Liu D#, Li B, Xu Z, Zhang P, Qin T, Qu S, Pan L, Sun X, Shi Z, Huang H, Wang H, Gale RP, Xiao Z*. RBC distribution width predicts thrombosis risk in polycythemia vera. Leukemia. 2022,36(2):566-568. (IF=12.883)

4. Liu D#, Xu Z, Zhang P, Qin T, Li B, Qu S, Pan L, Cai W, Liu J, Wang H, Sun Q, Sun X, Jiao M, Gao Q, Shi Z, Huang H, Huang G, Gale RP, Xiao Z*. Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera. Blood Cancer J. 2021,11(9):154. (IF=9.812)

5. Huang H#, Xu C#, Gao J#, Li B, Qin T, Xu Z, Ren S, Zhang Y, Jiao M, Qu S, Pan L, Hu N, Liu J, Cai W, Zhang Y, Wu D, Zhang P, Gale RP, Huang G, Zhou J, Shi L*, Xiao Z*. Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre. Blood Cancer J. 2020,10(8):83. (IF=11.037)

6. Hayashi Y#, Zhang Y#, Yokota A#, Yan X, Liu J, Choi K, Li B, Sashida G, Peng Y, Xu Z, Huang R, Zhang L, Freudiger GM, Wang J, Dong Y, Zhou Y, Wang J, Wu L, Bu J, Chen A, Zhao X, Sun X, Chetal K, Olsson A, Watanabe M, Romick-Rosendale LE, Harada H, Shih LY, Tse W, Bridges JP, Caligiuri MA, Huang T, Zheng Y, Witte DP, Wang QF, Qu CK, Salomonis N, Grimes HL, Nimer SD, Xiao Z*, Huang G*. Pathobiologic Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes. Cancer Discov, 2018, 8(11):1438-1457. (IF=26.37)

7. Luo X#, Xu Z#, Li B#, Qin T, Zhang P, Zhang H, Fang L, Pan L, Hu N, Qu S, Zhang Y, Huang G, Peter Gale R, Xiao Z*. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response. Blood Cancer J. 2018,8(1):9. (IF=7.895, R)

8. Wang J#, Xu Z#, Liu L#, Gale RP, Cross NC, Jones AV, Qin T, Ai X, Xu J, Zhang T, Sun X, Li Q, Zhang P, Zhang Y, Xiao Z*. JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms. Leukemia,2013,27(8):1763-1767. (IF=9.379)

9. Xu Z#, Gale RP, Zhang Y, Qin T, Chen H, Zhang P, Zhang T, Liu L, Qu S, Xiao Z*. Unique features of primary myelofibrosis in Chinese. Blood. 2012,119(11):2469-73. (IF=9.060, F1000)

10. Xiao Z#*, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma. 2002,43(9):1763-8. (IF=1.335, C100)


主站蜘蛛池模板: 泽州县| 乌鲁木齐县| 宁德市| 夏津县| 灌阳县| 灌云县| 扎鲁特旗| 讷河市| 石首市| 营口市| 东莞市| 遵化市| 玉田县| 安仁县| 乌兰察布市| 阿克苏市| 革吉县| 荥经县| 广西| 盘山县| 阿克| 三都| 嘉峪关市| 尼勒克县| 谷城县| 靖远县| 建宁县| 清苑县| 桦川县| 界首市| 南昌县| 孟州市| 个旧市| 阳朔县| 虹口区| 晋州市| 双桥区| 安多县| 布拖县| 云林县| 海宁市|